Related Experiment Video

Updated: Nov 7, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

594

Overexpression of Janus kinase 2 protein in extramammary Paget's disease

Saki Otsuka-Maeda1, Myangat Tselmeg Mijiddorj1, Ikko Kajihara1

  • 1Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Japanese Journal of Clinical Oncology
|April 29, 2021
PubMed

Insights

Extramammary Paget's disease, a rare skin cancer, shows high expression of Janus kinase 2 (JAK2). Increased JAK2 levels correlate with advanced disease, suggesting it as a potential therapeutic target for this condition.

Area of Science:

  • Oncology
  • Dermatology
  • Molecular Biology

Background:

  • Extramammary Paget's disease (EMPD) is a rare skin malignancy primarily affecting the genitocrural area.
  • Prognosis for EMPD with distant metastasis is poor, and effective therapies remain limited.
  • Janus kinase 2 (JAK2) is recognized as a potential therapeutic target in various cancers.

Purpose of the Study:

  • To investigate the expression of Janus kinase 2 (JAK2) protein in EMPD tissues.
  • To determine the correlation between JAK2 expression levels and the clinical significance in EMPD patients.

Main Methods:

  • Utilized immunohistochemistry to detect JAK2 protein expression in 53 EMPD tissue samples.
  • Correlated JAK2 immunostaining intensity with clinicopathological features, including invasiveness and metastasis.

Main Results:

  • JAK2 protein expression was detected in 94.3% (50/53) of EMPD tissues.
  • Higher JAK2 immunostaining intensity was significantly associated with increased invasiveness, lymph node metastasis, and distant metastasis.

Conclusions:

  • Janus kinase 2 (JAK2) is frequently expressed in Extramammary Paget's disease.
  • JAK2 expression levels correlate with adverse prognostic factors in EMPD.
  • JAK2 represents a promising therapeutic target for managing Extramammary Paget's disease.
Keywords:
EMPDJAK2JAK2 inhibitordermatologygeneticsgenetics-cancerskin

More Related Videos

Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

606
Establishment of a Clinic-based Biorepository07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

6.7K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.2K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.2K